Abcellera is Canada’s most valuable biotech company. It licensed its antibody for COVID 19 called bamlanivimab to Eli Lilly. This licensing deal has lead to monumental royalties of US$233M in revenue and US$119M in net profit. A winner beyond words.
Bamlanivimab is used to reduce hospitalizations by up to 80% in recently diagnosed patients and reduces the risk of getting infected in high risk environments such as nursing homes by 80%.
AbCellera has a block buster drug on the move with approval in 15 countries, exept it is NOT available in Canada.
That is a head scratcher! 15 regulatory agencies approve the drug. Canada took a pass. Health Canada did not approve the drug.
So does that mean that rationing is more important than saving lives in Canada.
Raymond Rupert patient advocate and health system disruptor.